Nu Ride Inc. (NRDE)
USD 1.2
(0.0%)
USD 1.2
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.34 Million | 194 Thousand | - | - | - |
| Cost of Revenue | 91.55 Million | 30.02 Million | 11.11 Million | - | - |
| Gross Profit | -89.21 Million | -29.82 Million | -11.11 Million | - | - |
| Operating Expenses | 75.95 Million | 246.08 Million | 389.37 Million | 102.48 Million | 10.39 Million |
| Selling, General and Administrative Expenses | 42.61 Million | 138.27 Million | 105.36 Million | 28.78 Million | 4.52 Million |
| Research and Development Expenses | 33.34 Million | 107.81 Million | 284.01 Million | 73.69 Million | 5.86 Million |
| Other Expenses | - | 788 Thousand | -10.07 Million | -20.86 Million | - |
| Cost and Expenses | 167.5 Million | 276.1 Million | 400.48 Million | 102.48 Million | 10.39 Million |
| Operating Income | -165.16 Million | -275.91 Million | -400.48 Million | -102.48 Million | -10.39 Million |
| Interest Expense | - | - | - | 703 Thousand | - |
| Income Tax Expense | - | - | - | 198 Thousand | -15.58 Million |
| Earnings before Tax | -343.06 Million | -282.4 Million | -410.36 Million | -124.05 Million | -10.39 Million |
| Net Income | -343.06 Million | -282.4 Million | -410.36 Million | -124.05 Million | -10.39 Million |
| Earnings Per Share Basic | -21.67 | -20.30 | -34.06 | -19.24 | -2.28 |
| Earnings Per Share Diluted | -21.67 | -20.30 | -34.06 | -19.24 | -2.28 |
| Weighted Average Shares Outstanding | 15.94 Million | 13.91 Million | 12.04 Million | 6.44 Million | 4.55 Million |
| Weighted Average Shares Outstanding (Diluted) | 15.94 Million | 13.91 Million | 12.04 Million | 6.44 Million | 4.55 Million |
| Gross Margin | -38.12 | -153.76 | - | - | - |
| EBIT Margin | -47.33 | -1378.55 | - | - | - |
| Profit Margin | -146.61 | -1455.69 | - | - | - |
| EBITDA | -110.75 Million | -267.43 Million | -399.25 Million | -123.34 Million | 5.19 Million |
| Earnings Before Tax Margin | -70.58 | -1422.24 | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 2.34 Million | - | 2.15 Million |
| Cost of Revenue | - | - | - | 91.55 Million | 99 Thousand | 60.73 Million |
| Gross Profit | - | - | - | -89.21 Million | -99 Thousand | -58.58 Million |
| Operating Expenses | 1.48 Million | 5.24 Million | 898 Thousand | 75.95 Million | 13.01 Million | 32.69 Million |
| Selling, General and Administrative Expenses | 1.48 Million | 5.24 Million | -15.36 Million | - | 7.4 Million | 20.38 Million |
| Research and Development Expenses | - | - | 898 Thousand | - | 5.61 Million | 12.3 Million |
| Other Expenses | -65 Thousand | -98 Thousand | 206 Thousand | 123 Thousand | -240 Thousand | 93 Thousand |
| Cost and Expenses | 1.48 Million | 5.24 Million | 898 Thousand | 167.5 Million | 13.11 Million | 93.43 Million |
| Operating Income | -1.48 Million | -5.24 Million | -898 Thousand | -165.16 Million | -13.11 Million | -91.27 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | -13.6 Million | - | - | - | - |
| Earnings before Tax | 1.47 Million | -8.47 Million | -349 Thousand | -343.06 Million | -16.5 Million | -154.49 Million |
| Net Income | 1.47 Million | -8.47 Million | -349 Thousand | -343.06 Million | -16.5 Million | -154.49 Million |
| Earnings Per Share Basic | 0.05 | -0.53 | -0.02 | - | -1.03 | -9.69 |
| Earnings Per Share Diluted | 0.05 | -0.53 | -0.02 | - | -1.03 | -9.69 |
| Weighted Average Shares Outstanding | 16.09 Million | 16.04 Million | 15.95 Million | 15.94 Million | 15.95 Million | 15.94 Million |
| Weighted Average Shares Outstanding (Diluted) | 17.53 Million | 16.04 Million | 15.95 Million | 15.94 Million | 15.95 Million | 15.94 Million |
| Gross Margin | - | - | - | -38.12 | - | -27.24 |
| EBIT Margin | - | - | - | - | - | -20.76 |
| Profit Margin | - | - | - | -146.61 | - | -71.82 |
| EBITDA | -1.48 Million | -5.24 Million | -898 Thousand | - | -13.01 Million | -44.64 Million |
| Earnings Before Tax Margin | - | - | - | -70.58 | - | -42.44 |
BLPFF
BARODARY
LINC
0217
IATR
SWID